Delta-Fly Pharma, Inc.

4598

JP3549370009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-13 EDT			5-day change	1st Jan Change
714 ^JPY	-1.92%		-3.38%	-29.66%

04-08	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
03-11	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion.

October 11, 2018 at 12:00 am

Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion. Security Name: Common Shares Security Type: Common Stock Securities Offered: 700,000 PriceRange: ¥4770 Discount Per Security: ¥381.6 Transaction Features: Sponsor Backed Offering

Latest news about Delta-Fly Pharma, Inc.

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	04-08	CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	03-11	CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	02-07	CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	02-02	CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	01-30	CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.	11-09	CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited	22-12-04	CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ã‘1.300842 billion in funding from Macquarie Group Limited	22-11-16	CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-23	CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	20-12-07	CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa	20-03-23	CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	19-11-26	CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019.	19-01-08	CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion.	18-10-11	CI
Delta-Fly Pharma, Inc. has filed an IPO.	18-09-05	CI
Delta-Fly Pharma, Inc. announced that it has received funding from Sanyo Chemical Industries Ltd.	18-03-22	CI

Chart Delta-Fly Pharma, Inc.

Duration

Period

More charts

Company Profile

Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
DELTA-FLY PHARMA, INC.	-29.66%	38.43M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals